Authorization for next-generation sequencing technologies

Equipment provider announces Certified Service Provider of genomic hybridization solutions.

Agilent Technologies Inc. (CA, USA) recently announced the authorization of an affiliate of Harvard Medical School, Massachusetts Eye and Ear Infirmary (MEEI; MA, USA), as a Certified Service Provider (CSP) of its next-generation target enrichment and microarray-based comparative genomic hybridization (aCGH) solutions.

Victor Fung, senior director of marketing for Agilent’s Genomics Solutions Division commented, “We are excited to have MEEI as part of the Agilent CSP program. MEEI has used Agilent’s next-generation sequencing target enrichment and aCGH solutions for several years in their retinal degeneration mutational disease research. We look forward to supporting them as they expand their services outside of the Harvard community.”

The medical school’s Department of Ophthalmology Ocular Genomics Institute based at MEEI is working towards using genomics and gene therapy to advance the knowledge and treatment of blinding eye diseases. Eric Pierce, director of the Ocular Genomics Institute, commented, “Becoming an Agilent CSP enables us to provide the ocular genomics research community with access to the latest protocols and technologies we are using at MEEI with ever-increasing success.”

Pierce added, “It is our hope that these tools will help advance studies in genomic research and gene therapy. In addition, incorporating the Agilent Bravo Automated Liquid Handling platform into our service offerings will enable us to quickly process large volumes of samples for even more researchers and for a wide range of genomics applications. We are using these approaches to provide improved clinical genetic diagnostic testing services for patients with inherited eye disorders.”

Source: Agilent Technologies names Massachusetts Eye and Ear Infirmary as Certified Service Provider for next-generation sequencing and aCGH solutions.